Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers have made a breakthrough in more precisely targeting drugs to cancers. Using ultrasound and lipid drug carriers (liposomes), a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anaesthetists at the University of Oxford have developed a new way to improve the targeting of cancer drugs to tumours.

None © Celsion

The new technology has been used in humans for the very first time, with ultrasound remotely triggering and enhancing the delivery of a cancer drug to the tumour.

“Reaching therapeutic levels of cancer drugs within a tumour, while avoiding side effects for the rest of the body is a challenge for all cancer drugs, including small molecules, antibodies and viruses” says Professor Constantin Coussios, Director of the Oxford Centre for Drug Delivery Devices (OxCD3) and of the Institute of Biomedical Engineering at the University of Oxford. “Our study is the first to trial this new technique in humans, and finds that it is possible to safely trigger and target the delivery of chemotherapy deep within the body from outside the body using focussed ultrasound. Once inside the tumour, the drug is released from the carrier, supplying a higher dose of chemotherapy directly to the tumour, which may help to treat tumours more effectively for the same or a lower systemic dose of the drug.”

Published in The Lancet Oncology journal, the 10-patient phase 1 clinical trial used focussed ultrasound from outside the body to selectively heat liver tumours and trigger drug release from heat-sensitive carriers, known as thermosensitive liposomes. Building on over a decade of preclinical studies, the study demonstrated the ultrasound technique to be feasible, safe, and capable of increasing drug delivery to the tumour between two-fold and ten-fold in the majority of patients. Ongoing research worldwide is investigating the applicability of this technique to other tumour types, and future research could explore the combination of ultrasound with other drugs.

All 10 patients treated had inoperable primary or secondary tumours in the liver and had previously received chemotherapy. The procedure was carried out under general anaesthesia and patients received a single intravenous dose of 50 mg/m2 of doxorubicin encapsulated within low-temperature-sensitive liposomes (ThermoDox®, Celsion Corporation, USA). The target tumour was selectively heated to over 39.5o C using an approved ultrasound-guided focussed ultrasound device (JC200, Chongqing HAIFU, China) at the Early Phase Clinical Trials Unit at the Churchill Hospital in Oxford. In six out of 10 patients, the temperature at the target tumour was monitored using a temporarily implanted probe, whilst in the remaining four patients ultrasonic heating was carried out non-invasively.

Before ultrasound exposure, the amount of drug reaching the tumour passively was low and estimated to be below therapeutic levels. In seven out of 10 patients, chemotherapy concentrations within the liver tumour following focussed ultrasound were between two and ten times higher, with an average increase of 3.7 times across all patients.

“Only low levels of chemotherapy entered the tumour passively. The combined thermal and mechanical effects of ultrasound not only significantly enhanced the amount of doxorubicin that enters the tumour, but also greatly improved its distribution, enabling increased intercalation of the drug with the DNA of cancer cells” says Dr Paul Lyon, lead author of the study.

“This trial offers strong evidence of the rapidly evolving role of radiology in not only diagnosing disease but also in planning, guiding and monitoring therapy. The treatment was delivered under ultrasound guidance and patients were subsequently followed up by CT, MRI and PET-CT, evidencing local changes in tumours exposed to focussed ultrasound” commented Professor Fergus Gleeson, radiology lead co-investigator for the trial.  

“A key finding of the trial is that the tumour response to the same drug was different in regions treated with ultrasound compared to those treated without, including in tumours that do not conventionally respond to doxorubicin” adds Professor Mark Middleton, principal investigator of the study. “The ability of ultrasound to increase the dose and distribution of drug within those regions raises the possibility of eliciting a response in several difficult-to-treat solid tumours. This opens the way not only to making more of current drugs but also targeting new agents where they need to be most effective. We can now begin to realize the promise of precision cancer medicine”.

The full paper, 'Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial,' can be read in The Lancet Oncology.

Media coverage

Heat-activated chemo shows promise in liver cancer patients
Health Imaging, 10/07/2018

Ultrasound can trigger and enhance drug delivery
Physics World, 23/07/2018

Meet the lead author of the study

Similar stories

Using artificial intelligence (AI) for safer CT imaging of blood vessels

Congratulations to Dr Regent Lee at the Nuffield Department of Surgical Sciences (NDS) who has been awarded a grant of £246,226 from Heart Research UK for his research project ‘Using artificial intelligence (AI) for safer CT imaging of blood vessels’.

Developing new ways to assess kidneys so transplants last for longer

With funding from Kidney Research UK, a team of researchers from the University of Oxford, the University of Nottingham and University College London will develop ways to assess donor kidneys and predict how well they will work after transplant.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Omair Shariq wins Best Clinical Paper at the American Association of Endocrine Surgeons 2021 Annual Meeting

Dr Omair Shariq, a DPhil student and clinical research fellow in the Nuffield Department of Surgical Sciences (NDS) and Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), has received the 2021 Best Presentation for Clinical Research award during the 41st Annual Meeting of the American Association of Endocrine Surgeons (AAES), which was held virtually on 25-27 April 2021.

Artificial intelligence tool for streamlining pathology workflow

A multidisciplinary team, comprising Andrea Chatrian, Dr Richard Colling, Professor Clare Verrill, Professor Jens Rittscher and colleagues, develops an algorithm for automated requesting of additional investigation in diagnostically uncertain prostate biopsies.

Latest issue of JNDS now online

The latest issue of the Journal of the Nuffield Department of Surgical Sciences (JNDS) is now available to read.

Blog posts

My virtual work experience with NDS and NDORMS

Louise Tan, a Year 12 student from Ballyclare in County Antrim, Northern Ireland, recently attended the joint NDS and NDORMS Virtual Work Experience. In this guest blog, Louise reflects on her experience.

Celebrating women of NDS

To celebrate 100 years since women were admitted as full members of the University and on the occasion of International Women's Day, a group of inspirational women in the Nuffield Department of Surgical Sciences (NDS) reflect on their journeys, their place in Medical Sciences and their vision for the next 100 years.

The life of a research nurse: supporting the Oxford COVID-19 Vaccine Trial

Research nurses in the NHS are playing a crucial role in helping to trial new coronavirus treatments and vaccines. Three NDS research nurses stepped up to help with the fight against this new disease. Here Bhumika Patel shares her experience of working on the Oxford COVID-19 Vaccine Trial.

Why I became a Peer Supporter

The Peer Support Programme was developed in recognition of the essential role students play in supporting and encouraging one another on a day-to-day basis throughout their time at university. NDS’ own Helen Stark discusses her experience of becoming a Peer Supporter.

Racism under the microscope

As Black History Month gets underway in the UK, NDS Athena SWAN Coordinator Emily Hotine puts racism under the microscope.